Arcellx, Inc. announced the release of new clinical data from its Phase 1 study of CART-ddBCMA in patients with multiple myeloma, and plans to present additional data at a conference and host a webcast with expert clinicians.
AI Assistant
ARCELLX INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.